title: Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering.
abstract: Residues important in the interaction between the 23-residue transmembrane (TM) domains of the integrin alpha(IIb)- and beta(3)-subunits were identified by mutating each non-Leu residue to Leu. Leu substitutions of alpha(IIb) at G972, G976, and T981, and of beta(3) at I693 and G708, increased ligand binding. Substitutions with other amino acids at alpha(IIb)G972 and beta(3)G708 could also increase ligand binding. The results are consistent with and extend the helical interface between the integrin alpha- and beta-subunit TM domains previously defined by cysteine scanning and disulfide bond formation. We differentiated between affinity- and valency-based modes of activation by TM domain mutations. The mutant alpha(IIb) W967C forms disulfide-linked alpha(IIb)-subunits within an (alpha(IIb)beta(3))(2) tetramer. This tetramer behaved as an ideal model for the valency mode of regulation, because it exhibited significantly increased binding to multivalent but not monovalent ligands and basally retained the bent conformation. By contrast, the activating Leu mutants showed increased binding to the monovalent, ligand-mimetic PAC-1 Fab and increased exposure of ligand-induced binding site (LIBS) epitopes, suggesting that they partially adopt an extended conformation. Furthermore, the previously described beta(3)G708N mutation in Chinese hamster ovary cells enhanced ligand binding affinity, not valency, and did not alter cell-surface clustering as defined by confocal microscopy. Our studies provide evidence that disrupting the integrin heterodimeric TM helix-helix interface activates ligand binding mainly by increasing the monomeric affinity for ligand, but not the receptor valency, i.e., clustering.
authors.affiliation: The CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA.
authors.forename: Bing-Hao
authors.initials: BH
authors.lastname: Luo
authors.forename: Christopher V
authors.initials: CV
authors.lastname: Carman
authors.forename: Junichi
authors.initials: J
authors.lastname: Takagi
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Springer
mesh_terms: D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D016466:CHO Cells; D002462:Cell Membrane / Q000737:chemistry; D006224:Cricetinae; D019281:Dimerization; D004220:Disulfides / Q000737:chemistry; D008024:Ligands; D008969:Molecular Sequence Data; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000737:chemistry*; D017433:Protein Structure, Secondary
chemical_list: D004220:Disulfides; D008024:Ligands; D019039:Platelet Glycoprotein GPIIb-IIIa Complex
references.citation: Cell. 2002 Sep 6;110(5):599-11
references.pmid: 12230977
references.citation: Biochemistry. 1992 Dec 29;31(51):12719-25
references.pmid: 1463743
references.citation: J Biol Chem. 1999 Sep 17;274(38):26869-77
references.pmid: 10480895
references.citation: J Biol Chem. 2004 Jun 25;279(26):27466-71
references.pmid: 15123676
references.citation: J Cell Biol. 2001 Dec 24;155(7):1319-32
references.pmid: 11756480
references.citation: Scanning Microsc. 1987 Jun;1(2):745-56
references.pmid: 3616571
references.citation: J Cell Biol. 2002 Sep 2;158(5):833-9
references.pmid: 12213832
references.citation: Curr Opin Cell Biol. 2003 Oct;15(5):547-56
references.pmid: 14519389
references.citation: J Cell Biol. 1984 Sep;99(3):822-9
references.pmid: 6088559
references.citation: Cell. 2004 Feb 6;116(3):431-43
references.pmid: 15016377
references.citation: Am Heart J. 1998 May;135(5 Pt 2 Su):S179-83
references.pmid: 9588397
references.citation: Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12462-7
references.pmid: 11606749
references.citation: Mol Cell Biol. 1987 Jan;7(1):379-87
references.pmid: 3031469
references.citation: Science. 2003 Sep 19;301(5640):1720-5
references.pmid: 14500982
references.citation: J Biol Chem. 2004 Jun 18;279(25):26666-73
references.pmid: 15067009
references.citation: Trends Biochem Sci. 1998 Jan;23(1):30-4
references.pmid: 9478133
references.citation: J Cell Biol. 2001 Jun 25;153(7):1427-40
references.pmid: 11425873
references.citation: Immunity. 2000 Dec;13(6):759-69
references.pmid: 11163192
references.citation: J Cell Biol. 2004 Dec 20;167(6):1241-53
references.pmid: 15611342
references.citation: J Biol Chem. 1994 Jul 22;269(29):18781-8
references.pmid: 7518445
references.citation: Biochem J. 2001 Jul 15;357(Pt 2):529-36
references.pmid: 11439104
references.citation: Nature. 2004 Nov 4;432(7013):59-67
references.pmid: 15378069
references.citation: Cell. 2002 Sep 20;110(6):673-87
references.pmid: 12297042
references.citation: Thromb Haemost. 1996 Dec;76(6):1038-46
references.pmid: 8972029
references.citation: Cell. 2002 Sep 6;110(5):587-97
references.pmid: 12230976
references.citation: Proc Natl Acad Sci U S A. 1987 Oct;84(20):7114-8
references.pmid: 2444974
references.citation: J Biol Chem. 1996 Mar 22;271(12):6571-4
references.pmid: 8636068
references.citation: J Biol Chem. 2003 Apr 25;278(17):15217-24
references.pmid: 12595537
references.citation: Science. 2003 May 2;300(5620):795-8
references.pmid: 12730600
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2403-8
references.pmid: 12604783
references.citation: J Clin Invest. 1996 May 1;97(9):2139-44
references.pmid: 8621804
references.citation: J Biol Chem. 1993 Nov 5;268(31):23087-92
references.pmid: 7693683
references.citation: Immunol Rev. 2002 Aug;186:141-63
references.pmid: 12234369
references.citation: PLoS Biol. 2004 Jun;2(6):e153
references.pmid: 15208712
references.citation: Immunol Rev. 2002 Aug;186:164-71
references.pmid: 12234370
references.citation: J Cell Biol. 1987 Jun;104(6):1655-63
references.pmid: 3584243